Palisade Bio, Inc. (PALI) SEC Filings — 2025

Filings

• Palisade Bio Files 8-K with Corporate Updates — 8-K · Dec 4, 2025
• Palisade Bio Narrows Losses, Secures $138M Equity Infusion — 10-Q · Nov 10, 2025
• Palisade Bio, Inc. DEFA14A Filing — DEFA14A · Nov 3, 2025
• Palisade Bio Seeks Shareholder Nod for 8.6M Warrant Issuance, Capital Boost — DEF 14A · Oct 28, 2025
• Palisade Bio Announces Director and Officer Changes — 8-K · Oct 22, 2025
• Palisade Bio Files 8-K on Security Holder Votes — 8-K · Oct 20, 2025
• Palisade Bio Relocates Principal Executive Offices — 8-K · Oct 16, 2025
• Palisade Bio Files 8-K: Financial Statements and Exhibits — 8-K · Oct 9, 2025
• Palisade Bio Files Proxy Statement — DEFA14A · Oct 7, 2025
• Palisade Bio Seeks Capital After Positive PALI-2108 Phase 1 Results — S-1 · Sep 29, 2025
• Palisade Bio Relocates Headquarters — 8-K · Sep 26, 2025
• Palisade Bio Relocates Principal Executive Offices — 8-K · Sep 18, 2025
• Palisade Bio Seeks Reverse Stock Split Approval at Annual Meeting — DEF 14A · Sep 15, 2025
• Palisade Bio, Inc. Reports Board Changes — 8-K · Sep 5, 2025
• Palisade Bio Files Definitive Proxy Statement — DEF 14A · Aug 18, 2025
• Palisade Bio Narrows Q2 Loss Amid R&D, G&A Cuts — 10-Q · Aug 11, 2025
• Palisade Bio, Inc. Files 8-K: Material Agreement & Equity Sales — 8-K · Jul 25, 2025
• Palisade Bio Appoints New CEO, Board Changes — 8-K · Jul 9, 2025
• Palisade Bio Files S-1 for Public Offering, Signaling Capital Raise — S-1 · May 27, 2025
• Palisade Bio Files Q1 2025 10-Q — 10-Q · May 12, 2025
• Palisade Bio Faces Delisting Concerns — 8-K · May 2, 2025
• Palisade Bio Files 2024 10-K — 10-K · Mar 24, 2025